Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow APVO
Aptevo Therapeutics Inc. (APVO) Piotroski F-score
Aptevo Therapeutics Inc.'s Piotroski F-score for fiscal 2022 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, up from 3 in fiscal 2021.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2022 | 4 | 1.00 |
| FY2021 | 3 | 0.00 |
| FY2020 | 3 | 0.00 |
| FY2019 | 3 | 1.00 |
| FY2018 | 2 | (4.00) |
| FY2017 | 6 | 4.00 |
| FY2016 | 2 | — |
How fiscal 2022’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 17.68% | (51.67%) | Pass | 1 |
| Positive operating cash flow | (21.02m) | (21.68m) | Fail | 0 |
| Rising return on assets | 17.68% | (51.67%) | Pass | 1 |
| Cash flow above net income | (29.05m) | 6.78m | Fail | 0 |
| Falling long-term leverage | 0.03 | 0.07 | Pass | 1 |
| Rising current ratio | 3.15 | 1.51 | Pass | 1 |
| No new shares issued | 5,100,000 | 4,688,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.07 | 0.22 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| EOCN Eocene Ltd. compare | 4 |
| APVO Aptevo Therapeutics Inc. | 4 |
| DCOY Decoy Therapeutics Inc compare | 4 |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 4 |
| ARAV ARAVIVE, INC compare | 3 |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 2 |
| CLDI Calidi Biotherapeutics, Inc. compare | — |
| GRI GRI Bio, Inc. compare | — |
| REVB Revelation Biosciences, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover